There have just been several important news that may have a significant impact on tomorrow's pharmaceutical sector, and I will give you an analysis:
Pharmaceutical Breaking News:
Fosun Pharma (600196) announced on the evening of April 17 that its holding subsidiary, Henlius, had recently obtained approval from the State Food and Drug Administration to carry out clinical trials of the self-developed HLX53 (anti-TIGIT Fc fusion protein) in combination with Hansizhuang (serplulimab injection) and Hanbeitai (bevacizumab injection) for the first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). In addition, Guilin Pharma, its holding subsidiary, was also accepted by the State Food and Drug Administration for its drug registration application for foscarnet sodium injection.
Sector market analysis:
Medicine yesterday in the yang rebound on Wednesday the yin line reversed, the pressure line synchronously recovered, today after the bottom of the pressure line after the small yang rebound, the strength is still not strong, the upper resistance area is still there, to strengthen must continue to break through the resistance, if even such a basic requirement has not been realized, for medicine is not an inflection point, even if the big yang line breaks through all the resistance, if it cannot form a continuous upward movement, it is only a shock market, so it is too early to be bullish on the pharmaceutical sector.
Healthcare Breaking News:
Jiuqiang Biotech (300406) announced that the company received the Rh blood typing card "Medical Device Registration Certificate" issued by the State Food and Drug Administration on the evening of April 17. This product is suitable for the detection of D, C, c, E and e antigens in the Rh blood group system, and is only used for clinical testing, not for blood screening.
Sector market analysis:
Medical yesterday in the yang rebound did not break through the pressure line, today after the bottom of the rebound finally stood on the pressure line, the gap formed on Tuesday to make up, the short-term short momentum has dissipated, but to be bullish medical, the pressure of the upper resistance area to overcome, if only there is a resistance area below the shock, there can also be a certain short-term gain, but the resistance area below the rebound security is very low, sometimes it is obviously the right logic, but the market will not give you a chance, equivalent to meaningless. It is better to wait for medical treatment to come out of a stronger rebound positive line and then consider being optimistic.
Biological Vaccine Breaking News:
Novozan announced on the evening of April 17 that it is expected to achieve a net profit of 4.5 million yuan to 5.5 million yuan in the first quarter of 2024, an increase of 55.12 million yuan to 56.12 million yuan over the same period last year, and successfully turned losses into profits. The company's life sciences business continued to launch new product lines such as extraction, cell, and protein, further enriching the product portfolio, and the rapid increase in customer unit price and market coverage, driving a significant increase in related sales revenue.
Sector market analysis:
Biological vaccine yesterday the big yang rebound anti-package Tuesday big black line, but like the medical, did not stand on the pressure line, today's pressure line moved in a narrow range, it is a passive recovery of the pressure line, the long power did not continue to strengthen, but for biological vaccines, it is already the norm, due to the lack of obvious bullish power, the recent weak rebound is a high probability, after the rebound is another round of adjustment, I think the success rate of such a rebound is not high, I will give up such a trend, never pay attention to such a weak rebound.
Special Notes:
1. The above content is just my own investment diary and does not have any guiding effect.
2. The views are for your reference only, and whether you can keep up with this idea is still up to you.
3. It is not easy to be original, if you think your article is good, please like and comment, it will be a great encouragement to me.